Skip to main content
Premium Trial:

Request an Annual Quote

Cypress Acquires Personalized Medicine Technology from Cellatope

NEW YORK (GenomeWeb News) – Cypress Bioscience has acquired Cellatope's technology platform for diagnosing and monitoring autoimmune disorders, such as lupus, for up to $5 million.

San Diego-based Cypress said that the technology platform uses cell-bound complement activation products for diagnosis and monitoring of response to treatment. It was developed by researchers at the Lupus center for Excellence at the University of Pittsburgh to evaluate cell-bound fragments of activated complement proteins and their utility in diagnosis and monitoring of lupus patients.

Cypress intends to complete development of the system and offer personalized medicine services to lupus patients. The firm already sells tests for therapeutic monitoring, diagnosis, and prognosis of patients with rheumatoid arthritis.

Cypress paid $2 million in cash to Cellatope for the CB-CAP technology and will make an additional $3 million potential milestone payment based on commercial development of the technology for lupus monitoring.

In connection with the acquisition, Cypress will assume a license from the University of Pittsburgh.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.